Le Lézard
Classified in: Health, Science and technology

2020 Europe Cell Surface Markers: Supplier Shares & Sales Segment Forecasts by Country, Innovative Technologies, Competitive Strategies & Opportunities for Suppliers - ResearchAndMarkets.com


The "2020 Europe Cell Surface Markers: France, Germany, Italy, Spain, UK - Supplier Shares and Sales Segment Forecasts by Country, Innovative Technologies, Competitive Strategies, Opportunities for Suppliers" report has been added to ResearchAndMarkets.com's offering.

The report provides an overview of the cell surface marker testing in Europe (France, Germany, Italy, Spain, UK), including 5-year forecasts for CD4, CD8, CD34 and other markers by country.

Rationale

The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies. During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.

This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in five European countries, including clinical significance and current laboratory practice, as well as five-year test volume forecasts by country and market segment.

The report examines market applications of monoclonal antibodies, IT, DNA probes, biochips/microarrays, and other Technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mn1d59


These press releases may also interest you

at 08:25
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell...

at 08:20
The "Highly Potent API Market - A Global and Regional Analysis: Focus on Type, Type of Synthesis, Therapeutic Area, Type of Manufacturing, End User, and Country - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...

at 08:15
Keysight Technologies , today announced its intention to acquire the entire issued and to be issued share capital of Spirent Communications PLC (London Stock Exchange Symbol: SPT) ("Spirent") for a cash consideration of 199 pence per Spirent share...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...

at 08:15
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms....



News published on and distributed by: